Gujarat Terce Laboratories Ltd
BSE: GUJTERC · Pharmaceuticals · sector
₹38.69BSE close 2026-10-26
Key numbers
Market cap₹30 cr
Price₹38.69
52w high / low₹53 / ₹29
P/E12.1xSector median 27.9x
P/B3.1xSector median 2.9x
Book value₹12.5
Dividend yield–Sector median 0.48%
ROE25.8%Sector median 11.7%
ROCE28.4%Sector median 12.3%
OPM6.2%Sector median 14.0%
Debt / equity0.13xSector median 0.16x
EV/EBITDA9.7xSector median 18.6x
Interest cover19.2x
Current ratio1.32x
Sales growth 3y+0.5%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹4 cr vs borrowings ₹1 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 19.2x in the last 12 months.
- Net loss in 3 of the last 6 quarters.
- Other income was 35% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹38.69 on 2026-10-26: -27.7% from the 52-week high, +33.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹87.43 · low ₹32.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 12 | 11 | 13 | 12 | 11 | 9 |
| EBITDA | 1 | -0 | 2 | 1 | 0 | -0 |
| OPM % | 8.5% | -0.2% | 14.6% | 9.3% | 2.5% | -5.4% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -3 | -0 | 1 | 1 | 0 | -0 |
| EPS (₹) | 9.14 | 0.12 | 1.89 | 0.95 | 0.13 | 0.23 |
| Revenue YoY | -7.5% | -17.1% | ||||
| Profit YoY | – | – |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 40 | 47 | 48 | 50 | 47 | 46 |
| EBITDA | 1 | -2 | 1 | 4 | 3 | 3 |
| Net profit | 1 | -2 | 0 | -1 | 2 | 2 |
| EPS (₹) | 1.18 | -2.25 | 0.33 | 2.62 | 2.92 | 3.20 |
| Revenue growth | +16.6% | +2.6% | +4.6% | -5.4% | – | |
| Profit growth | -292.0% | – | -508.3% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +0.5% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -29.0% (2y) | -28.1% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 6 | 10 |
| Borrowings | 1 | 1 |
| Cash & equivalents | 1 | 4 |
| Total assets | 23 | 25 |
| Fixed assets | 4 | 3 |
| Capital work in progress | 0 | – |
| Investments | 0 | 0 |
| Receivables | 5 | 5 |
| Inventory | 4 | 4 |
| Payables | 4 | 2 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 3 | 2 |
| Cash from investing | 0 | -0 |
| Cash from financing | -3 | 0 |
| Capex | 0 | 0 |
| Free cash flow | 3 | 2 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -15.1% | 22.6% |
| ROCE % | 51.3% | 29.1% |
| Debtor days | 37 | 37 |
| Inventory days | 71 | 79 |
| Payable days | 70 | 34 |
| Cash conversion cycle (days) | 38 | 82 |
| Working capital days | -4 | 27 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| GUJTERC | ₹30 cr | 12.1x | 3.1x | 25.8% | 28.4% | 6.2% | +0.5% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | GUJTERC |
| BSE code | 524314 |
| ISIN | INE499G01013 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.